Biotech was easily the top performer as August drew to a close.
Gilead Sciences (GILD) fired up the biotech sector with its nearly $12 billion buyout of Kite Pharma (KITE) and progress with its immunotherapy cancer treatment in development.
Biotech was easily the top performer as August drew to a close.
Gilead Sciences (GILD) fired up the biotech sector with its nearly $12 billion buyout of Kite Pharma (KITE) and progress with its immunotherapy cancer treatment in development.